Welcome to our dedicated page for Olema Pharmaceuticals SEC filings (Ticker: OLMA), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Olema Pharmaceuticals, Inc. filings document the regulatory record of a clinical-stage oncology company with common stock listed on the Nasdaq Global Select Market under OLMA. The company’s disclosures cover its targeted-therapy pipeline, including palazestrant and OP-3136, as well as financial results, liquidity updates, capital-structure matters, and Regulation FD investor materials.
Olema’s SEC filings also record material agreements, including lease arrangements, and governance matters such as board appointments, officer departures, indemnification agreements, compensation arrangements, and equity awards. Proxy materials address director elections, executive compensation, equity incentive plans, pay-versus-performance disclosure, and shareholder voting matters.
An insider has filed a Rule 144 notice to sell 50,000 shares of common stock through Fidelity Brokerage Services on NASDAQ, with an aggregate market value of $1,380,112.65. The shares relate to common stock where the number of shares outstanding is listed as 68,659,923, and the approximate sale date is given as 01/13/2026.
The securities to be sold were acquired on 01/13/2026 via an option granted on 02/01/2023, with 50,000 shares acquired for cash. Over the past three months, the notice reports prior sales of 51,000 common shares on 12/19/2025 for gross proceeds of $1,553,447.42 by David C. Myles and 10,000 common shares on 01/12/2026 for gross proceeds of $283,362.96 by Myles Properties, Inc. The signer represents that they do not know of any undisclosed material adverse information about the issuer’s operations.
Olema Pharmaceuticals reported that its preliminary, unaudited cash, cash equivalents and marketable securities as of December 31, 2025 were greater than $500 million. This early estimate is based on year-end data but may change once the company completes its full financial closing procedures and audit for the 2025 fiscal year.
The company emphasized that this cash figure is preliminary, unaudited, and should not replace the detailed financial statements that will appear in its upcoming annual report on Form 10-K. Olema also posted an investor presentation on its website and furnished it as an exhibit, providing additional background for investors and other stakeholders.
OLMA received a Form 144 notice indicating an intent to sell up to 10,000 shares of its common stock through Fidelity Brokerage Services LLC on or about 01/12/2026 on the NASDAQ market, with an aggregate market value of $283,362.96 at the time of the notice. These 10,000 shares were originally acquired on 06/30/2014 from the issuer via a convertible note transaction paid in cash. The notice also reports that security holder David C. Myles sold 51,000 common shares on 12/19/2025 for gross proceeds of $1,553,447.42. By signing, the seller represents that they are not aware of undisclosed material adverse information about the issuer’s operations.
Olema Pharmaceuticals, Inc. director reported an option exercise and a subsequent charitable gift of common stock. On 11/21/2025, the reporting person exercised a stock option and acquired 35,868 shares of Olema common stock at an exercise price of $0.39 per share. After this exercise, the same number of shares was held directly.
On 11/25/2025, the reporting person transferred 35,868 shares as a bona fide gift for no consideration to the Rappaport Family Foundation, a charitable foundation where the reporting person serves as an officer and has voting and dispositive power over the securities it owns. Following the reported transactions, the reporting person no longer holds Olema shares directly but reports 385,965 shares held indirectly through the Rappaport Family Trust, of which the reporting person is co‑trustee.
Olema Pharmaceuticals, Inc. (OLMA) announced a follow-on public offering of 10,000,000 shares of common stock at $19.00 per share under an existing shelf registration. The company expects the offering to close on November 20, 2025, subject to customary conditions, and has granted underwriters a 30-day option to purchase up to an additional 1,500,000 shares at the public offering price less underwriting discounts and commissions.
The transaction is expected to generate approximately $190.0 million in gross proceeds for Olema before underwriting discounts, commissions, and estimated expenses, assuming the underwriters do not exercise their option. The deal is led by TD Securities (USA) LLC as representative of the underwriters, and Olema has provided customary representations, warranties, indemnification and closing conditions as part of the underwriting agreement.
Olema Pharmaceuticals, Inc. is conducting a primary public offering of 10,000,000 shares of common stock at $19.00 per share. The company has also granted underwriters a 30-day option to purchase up to 1,500,000 additional shares at the same price, less underwriting discounts and commissions. Gross proceeds are $190,000,000, with estimated net proceeds of about $178,000,000 after $11,400,000 in underwriting discounts and commissions and offering expenses.
As of September 30, 2025, Olema had 68,652,730 shares outstanding, so this offering represents a meaningful increase in the share count before any underwriter option is exercised. Management plans to use the cash, together with existing resources and a loan facility, to fund late-stage clinical development and potential U.S. commercial launch of lead breast cancer therapy palazestrant and to advance second program OP-3136, with funding expected to support operations into 2028.
Olema Pharmaceuticals, Inc. is launching a primary offering of common stock and pre-funded warrants under its effective shelf registration to raise cash for its pipeline. Investors may buy either common shares or, for certain investors, pre-funded warrants that are immediately exercisable at an exercise price of $0.0001 per share and are not expected to trade on an exchange. The company’s common stock trades on the Nasdaq Global Select Market under the symbol OLMA and last closed at $8.52 per share on November 17, 2025.
Olema plans to use the net proceeds, together with existing cash, cash equivalents, marketable securities and borrowing capacity, to continue late-stage development of its lead breast cancer candidate palazestrant (OP-1250) and its second program OP-3136, and for working capital and general corporate purposes. Based on current plans, Olema believes these resources, including this offering, will fund operations into 2028, supporting a potential U.S. commercial launch of palazestrant in late 2027 if clinical trials are successful and the FDA grants approval. Shares outstanding were 68,652,730 as of September 30, 2025.
Olema Pharmaceuticals, Inc. reported that it has terminated its existing at-the-market prospectus used for sales of its common stock under a Sales Agreement with TD Securities (USA) LLC. This means the company will no longer sell shares through that at-the-market program unless and until it files a new prospectus, prospectus supplement, or registration statement. The underlying Sales Agreement itself remains in effect, so Olema could resume at-the-market sales in the future once new offering documents are in place.
Olema Pharmaceuticals (OLMA) reported Q3 2025 results, highlighting higher operating spend as its breast cancer programs advance. The company posted a net loss of $42.2 million, compared with $34.6 million a year ago. Research and development was $40.0 million and general and administrative was $5.9 million, reflecting continued clinical activity.
Liquidity remains strong, with $329.0 million in cash, cash equivalents and marketable securities at September 30, 2025, and an additional $22.0 million available under its loan facility. Stockholders’ equity was $307.5 million. The company’s weighted average share count was 85.7 million, which includes the effect of pre-funded warrants.
Olema has an at-the-market program of up to $150.0 million established in January 2025 with no sales to date. Previously, a November 2024 private placement raised $250.0 million gross (net approximately $237.0 million). As of November 5, 2025, 68,659,923 shares were outstanding; there are 17,094,163 shares issuable upon exercise of pre-funded warrants at $0.0001 per share, subject to beneficial ownership limits.
Olema Pharmaceuticals (OLMA) furnished an update on its business by reporting financial results for the quarter ended September 30, 2025. The company submitted a Current Report on Form 8-K under Item 2.02 and included a press release as Exhibit 99.1. The disclosure is designated as furnished, not filed, under the Exchange Act, meaning it is not subject to Section 18 liabilities and is incorporated by reference only if specifically stated.